Lawmaker Needles FDA Over Avandia Vote Details

Law360, New York (October 29, 2007, 12:00 AM EDT) -- A U.S. senator is asking the U.S. Food and Drug Administration to respond to accounts that an internal drug safety oversight board voted earlier in October to keep GlaxoSmithKline’s diabetes drug Avandia on the market by a one-vote margin amid agency considerations of a second warning for the drug label about heart attack risks.

U.S. Sen. Charles Grassley (R-Iowa), who is the ranking Republican on the Senate Finance Committee, said in a letter to FDA commissioner Andrew C. von Eschenbach on Monday that committee investigators learned...
To view the full article, register now.